Another dust-up over Vytorin
Executive Summary
Merck and Schering-Plough delayed reporting second-quarter earnings, scheduled for before the market opened on July 21, until after the end of the trading day so they could address a cancer risk signal in the SEAS trial for Vytorin, a combination of Merck's Zocor (simvastatin) and Schering's Zetia (ezetimibe). An independent oncology review panel said that patients taking Vytorin are not at increased risk for cancer despite a troubling signal from pooled study data for the combo product. However, the only positive result from the trial was a statistically significant proportional reduction in the secondary endpoint of atherosclerotic events alone. There was no significant difference between Vytorin and placebo on the combined primary endpoint of major cardiovascular events caused by either atherosclerosis or aortic valve disease, or by aortic stenosis alone. Vytorin already suffered a major setback when it failed to affect progression of atherosclerosis in the ENHANCE trial; two more Vytorin studies, SHARP and IMPROVE-IT, are ongoing (1"The Pink Sheet," April 7, 2008, p. 4)
You may also be interested in...
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
CHICAGO - With the full presentation of the results of the failed ENHANCE study at the American College of Cardiology annual meeting, a ringing endorsement for statin use and the results of IMPROVE-IT four years away, the door seems almost closed on Merck/Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.